ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Breast Cancer

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, presenting results of the trial; photo © ASCO/Scott Morgan 2017

Breast Cancer

The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer.

The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer.

The use of bisphosphonates was not associated with a decrease in the incidence of breast cancer in postmenopausal women, contrary to hypothesis.

A 46-year-old woman had a routine screening mammogram that showed new calcifications in the posterior left breast. A diagnostic mammogram showed several small punctate calcifications, and a 6-month interval follow-up was recommended.

T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor–positive breast cancer, according to a new randomized trial.

A 70-gene expression score can identify women with indolent breast cancer at “ultralow” risk, according to a new study. Women with such a score have extremely low risk of disease-specific mortality over 20 years without systemic therapy.

A recent study shows that many women with early-stage breast cancer are still undergoing unnecessary chest CT, despite NCCN recommendations.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.